About 25--40% of blacks in the United States are neutropenic; neutropenia is also prevalent in African and Afro-Caribbean populations ([@b20]; [@b1]; [@b5]; [@b2]; [@b8]; [@b4]). Previous studies comparing Afro-Caribbean and African immigrants to people of African descent born in the United Kingdom found that both groups had similar white blood cell counts (WBC) and absolute neutrophil counts (ANC) and that both groups' counts were lower than those of UK-born people of European descent. A study of white blood cell response to running a marathon, a reflection of release of neutrophils from bone marrow stores in response to cortisol, showed that runners of African ancestry had a smaller increase in WBC and ANC than white or Asian runners ([@b2]). The WBC response to brief intense exercise, which reflects neutrophil demargination in response to catecholamine release, has also been found to be lower in people of African descent than in those of European descent ([@b16]). Diet, lifestyle and geographic location appear unlikely to explain the racial differences in leucocyte measures ([@b1]), but their biological causes are also not understood.

We recently found that women of African descent with early-stage breast cancer had lower baseline WBC and longer duration of adjuvant chemotherapy than non-Hispanic white women ([@b6]). Black women were more likely to miss cycles of chemotherapy and had poorer survival than white women. These observations raised questions about whether the prevalence of low WBC varied among ethnic subgroups and how WBC might be related to other biomarkers among women without cancer. Such biomarkers might also help to identify patients with sickle cell disease who would be at increased risk for neutropenia during treatment with hydroxycarbamide (hydroxyurea) ([@b3]).

The gene that controls expression of the Duffy antigen receptor for chemokines (*DARC*), located on chromosome 1, has long been known to be associated with race. Within the gene, the single nucleotide polymorphism (SNP) most strongly associated with race is *DARC* rs2814778 ([@b13]). The CC genotype is present among 70--75% of blacks and is rare among whites in the United States. Among individuals with the CC genotype, *DARC* is not expressed (<http://www.utdol.com/utd/content/topic.do?topicKey=transfus/11818&view=text>). The same genotype was also recently reported to be associated with low WBC ([@b13]).

We analysed the association of *DARC* rs2814778 genotype with WBC and ANC, as well as other factors thought to be associated with WBC, in an ethnically diverse sample of women without serious illness.

Patients and methods
====================

Study design
------------

For this cross-sectional study, we recruited women aged 20--70 years who identified themselves as coming from the United States (US) or one of the Caribbean countries of origin chosen for analysis: Barbados/Trinidad-Tobago, the Dominican Republic, Haiti, and Jamaica. US-born women were eligible if they were either black and had US-born parents, or white. For statistical purposes based on power calculations, we aimed to recruit 40 subjects per ethnic group. Participants represented a convenience sample recruited at Columbia University Medical Center in upper Manhattan or Long Island University in Brooklyn.

Women were screened for enrolment according to place of birth, age at immigration, primary language, current age and medical history. Women who reported a specific illness or disease-related symptoms were excluded from the study.

After obtaining informed consent, we asked the study participants to respond to a questionnaire about demographic and behavioural factors and health history and to provide a blood specimen. A phlebotomist performed venipuncture to obtain a 10 ml blood sample in a yellow-top tube (citrate). Subjects received financial compensation for their participation. Between October 2003 and February 2006, 276 women were enrolled; 13 were excluded because their questionnaire was lost, their blood sample had clotted, or their country of origin was not one of those included in the study; two were excluded because of human immunodeficiency virus infection.

Laboratory procedures
---------------------

The Herbert Irving Comprehensive Cancer Center (HICCC) Biomarker Shared Resource and special hematology laboratory at Columbia University Medical Center performed all the analyses except for genotyping. The complete blood counts were determined by Sysmex^TM^ Automated Hematology Analyzer XE-2100. Tumour necrosis factor-alpha (TNF-α) levels were measured with the Human TNF-α/TNFSF1A Immunoassay kit (Quantikine HS; R&D Systems, Minneapolis, MN, USA), granulocyte colony-stimulating factor (G-CSF) levels with the G-CSF Immunoassay kit (Quantikine HS), granulocyte macrophage-colony stimulating factor (GM-CSF) levels using the GM-CSF Immunoassay kit (Quantikine HS), and C-reactive protein (CRP) levels with the High Sensitivity CRP Enzyme Immunoassay Test kit (Life Diagnostics, Inc., West Chester, PA, USA). All immunoassays were performed in duplicate, according to manufacturers' instructions ([@b4]).

*ELA2* polymorphisms ([@b7]) were detected by Sanger dideoxy DNA sequencing of genomic DNA. Polymorphisms indicative of African ancestry, including the rs2814778 SNP, were analyzed using the Sequenom MassARRAY platform and iPLEX Gold chemistry at the Children's Hospital of Oakland Research Institute (CHORI) Functional Genomics Core ([@b11]; [@b24]; [@b13]). The MassARRAY platform utilized multiplexed (up to 36-plex) polymerase chain reaction-based target amplification/single-base extension (SBE) coupled with allelic discrimination based on mass differences of SBE products. Detection of mass spectra was achieved with Matrix Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry.

Individual genetic ancestry was estimated by a maximum likelihood approach ([@b22]).

Statistical analysis
--------------------

The frequency distribution of the rs2814778 genotypes (CC, TC, or TT) was analysed by national origin, median ANC, cytokine (TNF-α, G-CSF and CRP) levels, and *ELA2* rs5784246 genotypes (CC, CA, or AA) using chi-square, Fisher's exact, and Kruskal--Wallis tests. We also analysed the correlation of ANC with African ancestry. The same variables were then included in a linear regression model with log-transformed ANC as the dependent variable. We set the statistical significance criterion as two-sided *P* ≤ 0·05.

Results
=======

Of the 261 women ([Table I](#tbl1){ref-type="table"}) who provided data for the analyses, 47 came from Barbados or Trinidad-Tobago, 50 from the Dominican Republic, 49 from Haiti, 37 from Jamaica, 75 from the United States (38 black and 37 white), and three from Europe (grouped with the US-born whites). The six study groups were similar with respect to age by Kruskal--Wallis test. Of the 183 study participants of Caribbean origin, only 25 (13·7%) were US-born (one whose parents came from Barbados, 14 from the Dominican Republic, four from Haiti and six from Jamaica).

###### 

Percentage distribution of Duffy (Fy) blood group system-associated SNPs by country of origin, ANC, cytokines, and *ELA2*rs57834246 allele status.

                                           CC     TC     TT     
  ---------------------------------- ----- ------ ------ ------ ----------
  Country (race)                                                
   Barbados/Trinidad-Tobago          45    69     20     11     0·0001
   Dominican Republic                50    8      40     52     
   Haiti                             49    75     25     0      
   Jamaica                           35    63     37     0      
   United States (black)             37    73     27     0      
   United States or Europe (white)   40    0      5      95     
   Overall                           256   47     26     27     
  Median ANC (×10^9^/l)                    2684   4212   3953   \<0·0001
  \% ANC ≤ 1500 × 10^9^/l            4·4   9·3    0      0      0·001
  TNF-α (pg/ml)                                                 
   Non-detectable                    134   48·5   28·4   23·1   0·65
   ≤233·3                            63    47·6   22·2   30·2   
   \>233·3                           59    44·1   23·7   32·2   
  G-CSF (ng/ml)                                                 
   \<0·0259                          85    32·9   27·1   40·0   0·002
   0·026--0·0381                     82    47·6   24·4   28·0   
   \>0·0381                          84    59·5   26·2   14·3   
  CRP (μg/ml)                                                   
   \<1·54                            116   44·0   25·9   30·2   0·84
   1·55--5·67                        66    29·3   22·7   25·8   
   \>5·67                            64    46·9   28·1   25·0   
  *ELA2* rs57834246 genotype                                    
   CC                                168   36·3   25·6   38·1   0·0001
   CA or AA                          75    69·3   24·0   6·7    

ANC, absolute neutrophil count; SNPs, single nucleotide polymorphisms; CRP, C-reactive protein; G-CSF, granulocyte colony-stimulating factor; TNF-α, tumour necrosis factor-alpha.

For the total sample of 261 women, the mean and median WBC were 6548 × 10^9^/l and 6200 × 10^9^/l respectively; the mean and median ANC were 3671 × 10^9^/l and 3306 × 10^9^/l.

The *DARC* rs2814778 genotypes were strongly associated with national origin ([Table I](#tbl1){ref-type="table"}). No US-born white women and only four Dominican women (8%) had the CC genotype (overall *P* = 0·0001). Women with the CC genotype had lower median ANC (*P* \< 0·0001) and higher G-CSF (*P* = 0·002), and were more likely to have the *ELA2* rs57834246 genotype (*P* \< 0·0001) than those with the TC and TT genotypes.

The median ANC for women with the CC genotype varied little by ethnic group (*P* = 0·91). However, the medians for women with the TC and TT genotypes ranged from 3544 (Caucasian) to 5963 (African American) and from 3444 (Caucasian) to 5304 (Barbadian/Trinidad-Tobago) respectively ([Fig 1](#fig01){ref-type="fig"}). Because of small sample sizes, these differences were not statistically significant (*P* = 0·08 for both TC and TT).

![Median ANC counts (x10^9^/l) by *DARC* rs2814778 genotype and ethnic group. The height of each bar represents the median ANC count for women with that genotype in that ethnic group. Above each bar are the percentage distributions of the genotypes in each ethnic group. Bar_Tri_T, Barbados/Trinidad-Tobago; Afi-Amer, African-American.](bjh0143-0288-f1){#fig01}

In the multivariate model ([Table II](#tbl2){ref-type="table"}), only the rs2814778 genotypes and CRP were associated with ANC (*P* = 0·0001).

###### 

Linear regression model of factors associated with log-transformed ANC.

                                  Beta       SD      *P*-value
  ------------------------------- ---------- ------- -----------
  *DARC* rs2814778 genotype                          
   CC                             Referent           
   TC                             0·445      0·080   \<0·0001
   TT                             0·476      0·128   \<0·0001
  \% African ancestry                                
   Below median                   Referent           
   Above median                   0·168      0·168   0·29
  Country of origin (race)                           
   United States (black)          Referent           
   Barbados/Trinidad-Tobago       0·023      0·124   0·85
   Dominican Republic             0·044      0·159   0·78
   Haiti                          0·014      0·126   0·91
   Jamaica                        −0·137     0·156   0·38
   United States/Europe (white)   0·108      0·243   0·66
  CRP (μg/ml)                                        
   \<1·54                         Referent           
   1·55--5·67                     0·076      0·068   0·26
   \>5·67                         0·27       0·069   0·0001
  G-CSF (ng/ml)                                      
   \<0·0259                       Referent           
   0·026--0·0381                  0·072      0·070   0·31
   \>0·0381                       0·045      0·073   0·54
  TNF-α (pg/ml)                                      
   Non-detectable                 Referent           
   ≤233·3                         −0·031     0·067   0·64
   \>233·3                        −0·100     0·070   0·16
  *ELA2*RS57834246 genotype                          
   CC                             Referent           
   CA or AA                       −0·038     0·067   0·57
  Income                                             
   ≤\$30 000                      Referent           
   \>\$30 000                     0·059      0·142   0·68
  Education                                          
   ≤12th grade                    Referent           
   \>12th grade                   −0·105     0·072   0·15
  Smoking                                            
   Never                          Referent           
   Ever                           −0·055     0·071   0·44

ANC, absolute neutrophil count; CRP, C-reactive protein; G-CSF, granulocyte colony-stimulating factor; TNF-α, tumour necrosis factor-alpha.

Discussion
==========

These findings confirm previous observations of an association of the *DARC* rs2814778 SNP with WBC ([@b13]). This study is, however, the first to show an association between the SNP and low ANC and to identify the association in subjects from the Caribbean as well as from the United States. Our findings also suggest that the low ANC phenotype may be recessive, given the lack of variability in ANC among women with the CC genotype. Women with the TC and TT genotypes had both higher and more variable ANC.

In a recent study of the same sample, clinical neutropenia was found in 12/171 women of African descent and 0/90 white and Dominican women with no reported explanatory medical conditions ([@b4]). Country of origin, *ELA2* rs57834246 genotype, and CRP, although not TNF-α, or G-CSF, were associated with ANC. The addition of *DARC* rs2814778 genotype to the model in the current study eliminated all those associations except for CRP.

The association observed in the current study between higher G-CSF and the *DARC* rs2814778 null homozygous genotype may reflect a feedback mechanism stimulated by low ANC ([@b19]). G-CSF has been shown both to increase neutrophil production and to accelerate neutrophil entry into the blood ([@b17]).

Individuals who lack DARC are resistant to *P. vivax* malaria because the merozoite uses DARC to enter red cells ([@b12]). Individuals who lack DARC on their red blood cells may still express it on their postcapillary venules, where it may interfere with leucocyte trafficking ([@b15]; [@b9]; [@b14]).

The mechanism for the association of neutropenia with the *DARC* SNP is unknown. One possibility is that individuals who lack DARC, by which red cells absorb cytokines, are unable to modulate white cell trafficking; hence their neutrophils pool and keep the circulatory ANC low. Such a mechanism might also account for poor mobilization of white cells in response to exercise and stress ([@b16]; [@b8]). One other possibility includes a decrease of bone marrow reserve due to a deficiency of granulocyte--macrophage colony-forming units ([@b2]; [@b18]).

Mice that were genetically engineered to lack DARC were unable to bind CXC chemokines, which promote tumorogenesis and angiogenesis ([@b10]). In a small study (*n* = 75) of human breast cancer pathological samples, high DARC expressors were less likely than low DARC expressors to have extensive lymph node metastases and had lower mortality ([@b23]).

A limitation of this study is that it is based on a convenience sample of women in the ethnic groups of interest. Recruitment took longer for some groups than for others and may have been subject to unknown biases. However, it is difficult to see how bias could account for the association observed between ANC and genotype, neither of which could have been known to the study participants or us prior to the analysis.

Another limitation is that the WBC and ANC were analysed in healthy women. We still know nothing about the association of neutropenia with genotype in the setting of cancer or any other disease. However, the purpose of the study was to learn more about the association between the study markers and ethnicity in the absence of disease.

A third limitation is that the *DARC* rs2814778 genotype may be merely a surrogate marker for another gene that is similarly distributed in the populations studied. However, that SNP is the one most strongly associated with race ([@b13]). Further studies may consider other candidate genes.

Conclusion
==========

This study is the first to show an association between the *DARC* rs2814778 CC genotype, common among individuals of African descent, and low ANC. The implications of this association for cancer patients and for those with sickle cell disease remain to be determined. For example, whether the effects of G-CSF as a treatment for chemotherapy-induced neutropenia among cancer patients, and of hydroxycarbamide as prevention for severe pain episodes among sickle cell patients([@b21]), vary by genotype needs to be determined. Further research may help to account for and prevent poor outcomes among persons of African ancestry and lead to interventions that may benefit them and all patients.
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